142 results on '"Simicek, Michal"'
Search Results
2. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma
3. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
4. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
5. Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti‐CD38 therapy.
6. Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti‐CD38 therapy
7. Length-Dependent Translation Efficiency of ER-Destined Proteins
8. Venetoclax: A new wave in hematooncology
9. Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma
10. Supplementary Table 3 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
11. Supplementary Figure 3 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
12. Supplementary Table 4 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
13. Supplementary Figure 2 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
14. Supplementary Figure 1 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
15. Supplementary Figure 4 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
16. Supplementary Table 1 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
17. Supplementary Table 2 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
18. Supplementary Figure 3 from Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition
19. Supplementary Figure Legends 1-4 from Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition
20. Supplementary Figure 2 from Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition
21. Supplementary Figure 4 from Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition
22. Supplementary Figure 1 from Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition
23. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma
24. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma
25. Deubiquitinase OTUD1 Resolves Stalled Translation on polyA and Rare Codon Rich mRNAs
26. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase (PSMC) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP/ATP Binding Pocket
27. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma
28. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
29. Mechanism of phospho-ubiquitin-induced PARKIN activation
30. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
31. Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
32. Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma
33. Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets
34. OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination
35. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
36. P-344 Multiomics profiling of extramedullary multiple myeloma tumors and their microenvironment
37. Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients
38. Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling
39. Intercellular Mitochondrial Transfer in the Tumor Microenvironment
40. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort
41. Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib
42. Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma
43. P-001: RNA-sequencing reveals transcriptomic similarity of AL amyloidosis and MGUS aberrant plasma cells along with several potential ALA target candidate genes
44. MUTATIONS IN 19S PROTEASOME SUBUNITS REPRESENT A NOVEL MECHANISM OF ACQUIRED RESISTANCE TO PROTEASOME INHIBITORS IN MULTIPLE MYELOMA PATIENTS
45. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
46. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)
47. Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma
48. P805: EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS.
49. Active site alanine mutations convert deubiquitinases into high‐affinity ubiquitin‐binding proteins
50. Active site alanine substitutions can convert deubiquitinating enzymes into avid ubiquitin-binding domains
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.